Edition:
United Kingdom

Sosei Group Corp (4565.T)

4565.T on Tokyo Stock Exchange

10,760JPY
18 Dec 2017
Change (% chg)

¥-110 (-1.01%)
Prev Close
¥10,870
Open
¥10,950
Day's High
¥10,950
Day's Low
¥10,660
Volume
216,200
Avg. Vol
474,581
52-wk High
¥14,580
52-wk Low
¥8,590

Select another date:

Fri, Nov 10 2017

BRIEF-Sosei Group to issue 2.1 mln new shares

* Says it plans to issue 2.1 million new shares through overseas offering

BRIEF-Sosei Group to advance clinical development in Japan of HTL0018318 in patients with Dementia with Lewy Bodies (DLB)

* Says it gains a licence to develop and commercialise HTL0018318, a novel muscarinic M1 receptor agonist, in Japan as a potential new treatment for patients with dementia with Lewy bodies (DLB)

BRIEF-Sosei Group unit says first subject dosed in Phase1 clinical study of novel selective muscarinic M4 agonist in development to treat major symptoms of Alzheimer's disease

* Says co's unit Heptares Therapeutics and Allergan announced that the first healthy subject has been dosed with the first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase 1 clinical study

BRIEF-Sosei Group to sell Chiba-based pharmaceutical unit for $3.5 mln

* Says it will sell Chiba-based pharmaceutical unit to Formosa Pharmaceuticals, Inc., which is unit of Formosa Laboratories, Inc, for $3.5 million

BRIEF- Sosei Group subsidiary Heptares enters strategic collaboration with PeptiDream

* Says its unit Heptares Therapeutics and PeptiDream Inc , a public Tokyo-based biopharmaceutical company, have entered into a strategic collaboration to discover, develop and commercialise novel therapeutics targeting an undisclosed G protein-coupled receptor (GPCR) with an important role in inflammatory diseases

Select another date: